PUBLISHER: DelveInsight | PRODUCT CODE: 1226637
PUBLISHER: DelveInsight | PRODUCT CODE: 1226637
"ORENCIA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ORENCIA for Rheumatoid Arthritis in the 7MM. A detailed picture of the ORENCIA for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the ORENCIA for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ORENCIA market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
ORENCIA is an immunomodulator that disrupts the continuous cycle of T-cell activation that characterizes RA. It is a selective T cell co stimulation modulator. ORENCIA is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is produced by recombinant DNA technology in a mammalian cell expression system. The apparent molecular weight of abatacept is 92 kilo Daltons. ORENCIA is the only RA biologic that offers three administration options: IV infusion, prefilled syringe and auto injector. ORENCIA for Injection is a lyophilized powder for intravenous infusion.
BMS and Ono also jointly develop and commercialize ORENCIA in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. ORENCIA experienced a reimbursement decreases in July 2021 due to new ASP calculation methodology.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ORENCIA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ORENCIA in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ORENCIA for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions